{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:19Z","timestamp":1790166199923,"version":"4.1.0"},"reference-count":55,"publisher":"Impact Journals, LLC","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,9,30]]},"DOI":"10.18632\/oncotarget.2353","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:38:12Z","timestamp":1442360292000},"page":"8637-8650","source":"Crossref","is-referenced-by-count":37,"title":["Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells"],"prefix":"10.18632","volume":"5","author":[{"given":"Hanyang","family":"Lin","sequence":"first","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"},{"name":"Department of Medicine, University of British Columbia, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Rothe","sequence":"additional","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"},{"name":"Department of Medical Genetics, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew V.","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"Discovery Medicine Oncology, Bristol-Myers Squibb, Princeton, NJ, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Woolfson","sequence":"additional","affiliation":[{"name":"Discovery Medicine Oncology, Bristol-Myers Squibb, Princeton, NJ, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Terry Fox Laboratory, British Columbia Cancer Agency, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"},{"name":"Department of Medicine, University of British Columbia, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"},{"name":"Department of Medical Genetics, University of British Columbia; Vancouver, BC, Canada V5Z 1L3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,8,16]]},"reference":[{"issue":"15","key":"1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia--advances in biology and new approaches to treatment","volume":"349","author":"Melo","year":"2003","journal-title":"The New England journal of medicine"},{"issue":"11","key":"2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia","volume":"24","author":"Eaves","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Griffin","year":"2003","journal-title":"Seminars in hematology"},{"issue":"3","key":"4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.20062335","article-title":"Oncogenic signaling: new insights and controversies from chronic myeloid leukemia","volume":"204","author":"Van Etten","year":"2007","journal-title":"The Journal of experimental medicine"},{"issue":"23","key":"5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Reiffers","year":"2006","journal-title":"The New England journal of medicine"},{"key":"6","article-title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib","author":"Leber","year":"2014","journal-title":"Blood"},{"issue":"5682","key":"7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Sawyers","year":"2004","journal-title":"Science"},{"issue":"11","key":"8","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","article-title":"Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance","volume":"116","author":"Ottmann","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Cavazza","year":"2005","journal-title":"Cancer cell"},{"issue":"5531","key":"10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"issue":"8","key":"11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"Deininger","year":"2012","journal-title":"Nature reviews Cancer"},{"issue":"11","key":"12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Rousselot","year":"2010","journal-title":"The lancet oncology"},{"issue":"5","key":"13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Cayuela","year":"2014","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"20","key":"14","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Bhatia","year":"2011","journal-title":"Blood"},{"issue":"9","key":"15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Eaves","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"16","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Eaves","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s13238-013-2115-0","article-title":"Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells","volume":"4","author":"Li","year":"2013","journal-title":"Protein & cell"},{"issue":"1","key":"18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Druker","year":"2011","journal-title":"The Journal of clinical investigation"},{"issue":"6","key":"19","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Holyoake","year":"2012","journal-title":"Blood"},{"issue":"3","key":"20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia","volume":"25","author":"Arlinghaus","year":"2011","journal-title":"Leukemia"},{"issue":"13","key":"21","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1158\/0008-5472.CAN-06-0025","article-title":"Janus kinase 2: a critical target in chronic myelogenous leukemia","volume":"66","author":"Arlinghaus","year":"2006","journal-title":"Cancer research"},{"issue":"6","key":"22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Paul","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"issue":"12","key":"23","doi-asserted-by":"crossref","first-page":"918","DOI":"10.18632\/oncotarget.405","article-title":"AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders","volume":"2","author":"Jiang","year":"2011","journal-title":"Oncotarget"},{"issue":"3","key":"24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Griffin","year":"1996","journal-title":"The Journal of experimental medicine"},{"issue":"49","key":"25","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"and Van Etten RA. P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ccr.2004.12.010","article-title":"Stat5 tetramer formation is associated with leukemogenesis","volume":"7","author":"Beug","year":"2005","journal-title":"Cancer cell"},{"issue":"12","key":"27","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Frank","year":"2011","journal-title":"Blood"},{"issue":"12","key":"28","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Sexl","year":"2011","journal-title":"Blood"},{"issue":"12","key":"29","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood-2011-11-395228","article-title":"JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths","volume":"119","author":"Tefferi","year":"2012","journal-title":"Blood"},{"issue":"7","key":"30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Tefferi","year":"2011","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Soll","year":"2008","journal-title":"Cancer cell"},{"key":"32","article-title":"Role of altered growth factor receptor mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells","author":"Bhatia","year":"2014","journal-title":"Blood"},{"issue":"6","key":"33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543784.2013.774373","article-title":"Investigational Janus kinase inhibitors","volume":"22","author":"Verstovsek","year":"2013","journal-title":"Expert opinion on investigational drugs"},{"issue":"13","key":"34","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia","volume":"122","author":"Sexl","year":"2013","journal-title":"Blood"},{"issue":"2","key":"35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/leu.2011.292","article-title":"Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2","volume":"26","author":"Hosbach","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"36","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.bjc.6602190","article-title":"Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation","volume":"91","author":"Bourhis","year":"2004","journal-title":"British journal of cancer"},{"issue":"2","key":"37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3747\/co.v15i2.224","article-title":"An approach to the management of chronic myeloid leukemia in British Columbia","volume":"15","author":"Smith","year":"2008","journal-title":"Curr Oncol"},{"issue":"35","key":"38","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Radich","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"39","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V92.4.1390","article-title":"The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic\/severe combined immunodeficiency mice reflect the phase of the donor's disease: anmodel of chronic myelogenous leukemia biology","volume":"92","author":"Gordon","year":"1998","journal-title":"Blood"},{"issue":"24","key":"40","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Bradley-Garelik","year":"2010","journal-title":"The New England journal of medicine"},{"issue":"27","key":"41","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Kan","year":"2004","journal-title":"Journal of medicinal chemistry"},{"issue":"14","key":"42","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients","volume":"28","author":"Arlinghaus","year":"2009","journal-title":"Oncogene"},{"issue":"5","key":"43","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Deininger","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"44","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Burchert","year":"2007","journal-title":"Blood"},{"issue":"10","key":"45","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Sun","year":"2013","journal-title":"The Journal of clinical investigation"},{"issue":"47","key":"46","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","article-title":"Jak2 is involved in c-Myc induction by Bcr-Abl","volume":"21","author":"Arlinghaus","year":"2002","journal-title":"Oncogene"},{"issue":"3","key":"47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Sexl","year":"2012","journal-title":"Nature chemical biology"},{"issue":"22","key":"48","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia","volume":"96","author":"Eaves","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"15","key":"49","first-page":"3426","article-title":"P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation","volume":"56","author":"Arlinghaus","year":"1996","journal-title":"Cancer research"},{"issue":"2","key":"50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nbt0214-119a","article-title":"Setback for JAK2 inhibitors","volume":"32","author":"Ratner","year":"2014","journal-title":"Nature biotechnology"},{"issue":"2","key":"51","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/leu.2013.205","article-title":"Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)","volume":"28","author":"Hantschel","year":"2014","journal-title":"Leukemia"},{"key":"52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Advances in enzyme regulation"},{"issue":"6","key":"53","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","article-title":"BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry","volume":"20","author":"Holyoake","year":"2006","journal-title":"Leukemia"},{"issue":"11","key":"54","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","article-title":"AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells","volume":"205","author":"Jiang","year":"2008","journal-title":"The Journal of experimental medicine"},{"issue":"6","key":"55","article-title":"Purification of RNA using TRIzol (TRI reagent)","volume":"2010","author":"Nilsen","year":"2010","journal-title":"Cold Spring Harb Protoc"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:24:47Z","timestamp":1748625887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,16]]},"references-count":55,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,9,30]]}},"alternative-id":["2353","25226617"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2353","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,16]]}}}